Longitudinal trajectories of polypharmacy in older people, and their association with the risk of mortality: A joint latent class model analysis of real-world data from the UK and the Netherlands

Leena Elhussein*, Ross D. Williams, Wai Yi Man, Edward Burn, Antonella Delmestri, Victoria Y. Strauss, Daniel Prieto-Alhambra

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

Objective Polypharmacy is the use of multiple drugs. Many definitions have been established for polypharmacy, often cross-sectionally, despite it naturally changing over time. In this study, we aimed to identify clusters of older people with distinct polypharmacy trajectories over time and associated mortality risks. We then characterised the identified clusters and assessed their generalisability in two external databases. Methods Data were extracted from three primary care databases: the UK Clinical Practice Research Datalink (CPRD) GOLD, CPRD Aurum and the Dutch Integrated Primary Care Information (IPCI). People aged ≥65 on 1 January 2015 were included. Polypharmacy, defined as the cumulative number of prescribed ingredients, was calculated at baseline and at the end of each subsequent follow-up year (2015-19). We applied joint latent class modelling, which divides the population into clusters with different trajectories and associated mortality risks. The model was trained in GOLD and validated in Aurum and IPCI. Results Four clusters were identified and characterised based on polypharmacy baseline and rate of progression: low-steady, intermediate-slow/increasing, intermediate-fast/increasing and high-decreasing. The high-decreasing cluster had the highest average baseline polypharmacy (intercept = 23.4) and prevalence of non-cancer chronic comorbidities, whilst the intermediate-fast/increasing had the steepest polypharmacy rate of progression per year (slope = 6.4), highest baseline and cumulative incidence of cancer, and worst survival outcome. Good validation was found in Aurum and IPCI. Conclusion High baseline levels and increasing levels of polypharmacy were associated with an increased mortality risk in older people. The clusters identified in this study were externally validated in two European databases, confirming their robustness and generalisability.

Original languageEnglish
Article numberafaf233
JournalAge and Ageing
Volume54
Issue number8
DOIs
Publication statusPublished - 1 Aug 2025

Bibliographical note

Publisher Copyright:
© 2025 The Author(s). Published by Oxford University Press on behalf of the British Geriatrics Society.

Fingerprint

Dive into the research topics of 'Longitudinal trajectories of polypharmacy in older people, and their association with the risk of mortality: A joint latent class model analysis of real-world data from the UK and the Netherlands'. Together they form a unique fingerprint.

Cite this